Status:
COMPLETED
Gram-negative Bacteremia in HSCT Recipients
Lead Sponsor:
European Society for Blood and Marrow Transplantation
Conditions:
Allogeneic or Autologous HSCT
Eligibility:
All Genders
Brief Summary
A significant increase in resistant bacteria emerging in HSCT recipients. For example, 25% - 42% of all enterobacteriaceae produce extended spectrum beta-lactamases; 8 - 72% of Pseudomonas aeruginosa ...
Detailed Description
Primary objective: To determine the incidence and pattern of antimicrobials resistance among Gram-negative bacteria isolated from blood in HSCT patients during the first 6 months after the transplant...
Eligibility Criteria
Inclusion
- Allogeneic or autologous HSCT recipients, of all ages, for any indications.
Exclusion
- Patients who are not willing to participate.
Key Trial Info
Start Date :
February 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2017
Estimated Enrollment :
591 Patients enrolled
Trial Details
Trial ID
NCT02257931
Start Date
February 1 2014
End Date
April 1 2017
Last Update
May 1 2017
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Gasthuisberg
Leuven, Belgium
2
First Affiliated Hospital of Soochow University
Suzhou, China
3
University Hospital Center Rebro
Zagreb, Croatia
4
University of Muenster
Münster, Germany